Prasad Pattabhi, Research Assistant

Prasad Pattabhi received his Master’s in Molecular Microbiology at the University of Hyderabad, India. After graduation, he was a CSIR-JRF (The Council of Scientific and Industrial Research (CSIR) Junior Research Fellow (JRF)- Project Associate under the supervision of Prof. Naresh Babu V Sepuri, where he studied oxidative protein folding and Fe-S cluster Regulation mechanisms for four years. Prompted by his expertise and interest in oxidative stress and cell death, Prasad has joined Scaglioni’s laboratory as Research Assistant in February 2023. He is currently assisting in several projects in focused on therapy resistance, lipid metabolism and ferroptosis in lung cancer.

Pier Paolo Scaglioni, MD

Pier Paolo Scaglioni, MD, is the Herbert F. Koch Professor of Medicine, and the Division Director for the Division of Hematology/Oncology. Dr. Scaglioni received his medical degree from the University of Modena Medical School, in Italy, in 1989, and completed his Hematology/Oncology fellowship at Memorial Sloan Kettering Cancer Center, New York City, NY, in 2005. Dr. Scaglioni specializes in malignant hematology and is currently the Interim Director of the George L. Strike Bone Marrow Transplant Program at the University of Cincinnati. Dr. Scaglioni also leads a research laboratory which consists of 2 Research Scientists, and a Senior Research Associate. His team is currently studying the effect of KRAS in non-small cell lung cancer. Dr. Scaglioni’s team has identified several cellular networks that are responsible for the survival of KRAS mutant lung cancer. Among these, his research team found that KRAS regulates the metabolism of fatty acid to make the complex lipids necessary for cell proliferation. Furthermore, his team found that KRAS promotes the survival of lung cancer cells by regulating the cellular networks that replace fatty acids that are damaged by free radicals. Because fatty acids have been long studied by metabolic researchers, drugs have been developed for conditions such as obesity and fatty liver disease. A Phase 1 trial using one of those drugs was completed in 2018 to test safety doses. In that trial, the drug appeared to slow tumor growth in 11 of the 17 patients. This drug is now in Phase II trials to measure its effectiveness.

Margherita Melegari, MD, PhD

Margherita Melegari completed her Medical degree and Ph.D. degree at the University of Modena, Italy with a focus on the Hepatitis B Virus and liver cancer. She specialized in Gastro-Intestinal and Liver diseases at the same University. Starting in 1991 she has worked in many USA research Labs (Massachusetts General Hospital, NYU, A. Einstein College of Medicine, UT Southwestern) working on Hepatitis B virus X transacting protein, miRNAs and cancer. She currently manages Dr. Scaglioni’s Lab and keeps busy with vectors building.